1 Month Retatrutide Results: Trial Evidence

Retatrutide is an investigational triple receptor agonist developed by Eli Lilly that has no marketing authorisation in the UK or elsewhere. Clinical trial data, including early findings from the Phase 2 study published in the New England Journal of Medicine in 2023, have reported measurable changes in body weight within the first weeks of treatment. This article summarises what the published trial evidence reports about one month retatrutide results, explains the limitations of those findings, outlines the side effects recorded in trials, and sets out the risks of attempting to obtain retatrutide outside an authorised clinical trial.

What is retatrutide and what is its regulatory status in the UK?

Retatrutide is an investigational triple agonist medicine with no UK marketing authorisation; it is available only inside authorised clinical trials and cannot be prescribed or advertised in the UK.

Retatrutide holds no marketing authorisation in the UK or anywhere else, and it is available only via authorised clinical trials, where it is administered and supplied by the trial team.^[13][1] It is an investigational medicine developed by Eli Lilly that acts simultaneously on three hormone receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor.^[3][4] This triple agonist mechanism is designed to reduce appetite, increase energy expenditure and improve glucose metabolism, though these effects have been studied only in trial populations under controlled conditions.

Because retatrutide has no UK marketing authorisation, the Medicines and Healthcare products Regulatory Agency (MHRA) has not evaluated it for safety and efficacy in the way it would a licensed medicine. The MHRA has also made clear that unlicensed medicines cannot be advertised, and no launch date or regulatory timeline can be given.^[1][2] People who are interested in licensed weight-management treatments can discuss the options that are currently available with their GP.

What did clinical trials report after one month of retatrutide?

Phase 2 trial data showed measurable body weight reductions within the first four weeks, but these figures reflect an early dose-escalation period and were not a primary trial endpoint.

Early data from the Phase 2 trial of retatrutide, published in the New England Journal of Medicine in 2023, reported measurable reductions in body weight within the first four weeks of treatment, though the trial was not designed to isolate or report one-month outcomes as a primary endpoint.^[3][4] Participants in that trial were adults with obesity or overweight and at least one weight-related comorbidity, and they received weekly subcutaneous injections at various dose levels over 24 and 48 weeks.^[3][4] Weight reductions observed at the earliest measured timepoints reflected the beginning of a dose-escalation period rather than a stable therapeutic dose.

The Phase 3 programme, which includes the TRIUMPH and TRANSCEND trial series, is providing more detailed and longer-term data across larger and more diverse populations, including people with type 2 diabetes.^[5][6] Results from TRANSCEND-T2D-1, published in The Lancet, represent the first Phase 3 readout and confirm that the programme is generating more rigorous efficacy and safety data than the Phase 2 work.^[5][6] Any figures reported at approximately one month in these trials represent an early point on a dose-escalation curve and should not be interpreted as the expected outcome for an individual, nor compared directly with results from trials of other medicines, which used different populations, designs and endpoints.

How reliable are the early trial findings, and what are their limits?

Early findings are limited by small Phase 2 sample sizes, sub-therapeutic escalating doses at one month, selective enrolment criteria, and the absence of head-to-head trials against licensed medicines.

Early retatrutide trial findings carry important limitations that affect how they should be interpreted. The Phase 2 trial enrolled a relatively small number of participants compared with the Phase 3 programme, and it was not powered to detect differences in clinical outcomes such as cardiovascular events or long-term weight maintenance. Results at early timepoints, including those around one month, reflect a period when participants are still on sub-therapeutic escalating doses, meaning they do not represent the effect of the medicine at its intended maintenance dose.

Trial populations are also carefully selected. Participants in retatrutide trials were required to meet specific inclusion criteria and were excluded if they were pregnant, breastfeeding or planning pregnancy, or if they had certain medical conditions. This means findings cannot be generalised to the broader population without further study. Additionally, trial conditions, including regular clinical monitoring, dietary guidance and structured follow-up, differ substantially from real-world use, which can influence outcomes in ways that are difficult to quantify.

Finally, no head-to-head trials comparing retatrutide directly with licensed medicines such as tirzepatide (Mounjaro) or semaglutide (Wegovy) have been conducted, so any comparison of trial figures across different studies is methodologically unreliable and should be treated with caution.

What side effects were recorded in retatrutide trials?

The most common side effects were gastrointestinal, including nausea, vomiting and diarrhoea; gallbladder disorders and cases of acute pancreatitis were also recorded in trial settings.

The most commonly reported side effects in retatrutide trials were gastrointestinal in nature, consistent with the GLP-1 receptor agonist class. These included nausea, vomiting, diarrhoea and constipation, and they occurred most frequently during the dose-escalation phase. In the Phase 2 trial, these effects were generally described as mild to moderate in severity and tended to diminish as participants remained on a stable dose, though some participants discontinued treatment because of them.^[3][4]

More serious adverse events recorded in trials included gallbladder-related disorders, which are a recognised concern across the GLP-1 receptor agonist class. Injection-site reactions were also reported. As with other medicines in this class, cases of acute pancreatitis have been reported in clinical trial settings, and participants with a history of pancreatitis were typically excluded from enrolment.^[3][4]

Because retatrutide is not a licensed medicine, its full safety profile has not been established to the standard required for a marketing authorisation. The TRIUMPH and TRANSCEND trial series are collecting longer-term safety data, and the complete picture will not be known until those results are fully reported and reviewed by regulators.

If you are enrolled in a retatrutide trial, the research team will advise you on contraception requirements; pregnancy must be avoided during participation, and you should contact the trial team urgently if you become pregnant or begin breastfeeding. It is also important to carry your trial participant card and to inform any emergency clinician that you are enrolled in a clinical trial, so that they can take your study medicine into account when treating you.

Anyone who experiences a suspected side effect while participating in an authorised clinical trial should report it to the trial team under the study protocol. Suspected side effects can also be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

What are the risks of sourcing retatrutide online or without a trial?

Any retatrutide sold outside an authorised trial has no legitimate supply chain, no approved manufacturing standard and no regulatory oversight, posing serious risks including contamination and incorrect dosing.

Any retatrutide sold online or outside an authorised clinical trial is not a licensed product and may be falsified, contaminated or incorrectly labelled. Because retatrutide has no marketing authorisation anywhere in the world, there is no legitimate commercial supply chain, no approved manufacturing standard and no regulatory oversight of any product presented as retatrutide outside a trial setting. Purchasing such a product carries serious risks to health, including exposure to unknown substances, incorrect dosing and the absence of any medical supervision.

Falsified injectable medicines are a particular concern because contamination or incorrect concentration can cause severe harm, including infection, allergic reactions or unpredictable pharmacological effects. There is no way for a consumer to verify the contents of an unlicensed product purchased online, regardless of how it is labelled or packaged.

People who are concerned about their weight or metabolic health are encouraged to speak with their GP, who can assess their individual circumstances and discuss licensed treatment options that have been evaluated for safety and efficacy by the MHRA. Attempting to obtain an investigational medicine outside a clinical trial bypasses the safeguards that exist to protect participants and does not provide access to the monitoring and support that trial enrolment includes. If you believe you have been sold a falsified or unlicensed medicine, you can report it to the MHRA via the 'Report a problem with a medicine or medical device' service on the MHRA website, or seek advice from NHS 111.

Frequently Asked Questions